Management of peritoneal surface component of ovarian cancer

Surgical Oncology Clinics of North America

Volumn 12, Issue 3, 2003, Pages 561-583

  Deraco, Marcello ^a   Raspagliesi, Francesco ^a   Kusamura, Shigeki ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; LIPOSOME; MITOXANTRONE; OXALIPLATIN; PACLITAXEL; TAMOXIFEN; TOPOTECAN; UNCLASSIFIED DRUG;

ADVANCED CANCER; AREA UNDER THE CURVE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG INDICATION; DRUG PENETRATION; FEMALE; HUMAN; HYPERTHERMIC THERAPY; ILEUS; MONOTHERAPY; OUTCOMES RESEARCH; OVARY CANCER; PERITONEAL DISEASE; PERITONEUM; PERITONEUM CANCER; REVIEW; SUBILEUS; SYMPTOM; TREATMENT INDICATION;

EID: 0042744853     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1055-3207(03)00027-9     Document Type: Review

References (102)

1. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the world-wide mortality from 25 cancers in 1990. Int J Cancer 1999;83(1):18-29.
2. Parkin DM, Pisani P, Ferlay J. Estimates of the world-wide incidence of 25 major cancers in 1990. Int J Cancer 1999;80(6):827-41.
3. McGuire WP, Hoskin WJ, Brady MF, Kucera PR, Patridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996;334:1-6.
4. De Gramont A, Drolet Y, Varette C, Louvet C, Gonzalez-Canall G, Krulik M, et al. Survival after second-look laparotomy in advanced ovarian epithelial cancer. Study of 86 patients. Eur J Cancer Clin Oncol 1989;25:451-7.
5. Gershenson DM, Copeland LJ, Wharton JT, Atkinson EN, Sneige N, Edwards CL, et al. Prognosis of surgically determined complete responders in advanced ovarian cancer. Cancer 1985;5:1129-35.
6. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47(2):159-66.
7. Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974-9.
8. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Clin Oncol 2002;20(5):1248-59.
9. Le T, Krepart GV, Lotocki RJ, Heywood MS. Does debulking surgery improve survival in biologically aggressive ovarian carcinoma. Gynecol Oncol 1997;67:208-14.
10. Covens AL. 74A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 2000;78(3 Pt 1):269-74.
11. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: prospective study. Gynecol Oncol 1998;69:103-8.
12. Michel G, De Iaco P, Castaigne D, El-Hassan MJ, Lobreglio R, Lhomme C, et al. Extensive cytoreductive surgery in advanced ovarian carcinoma. Eur J Gynecol Oncol 1997;18:9-15.
13. Brand E, Pearlman N. Electrosurgical debulking of ovarian cancer: a new technique using the argon beam coagulator. Gynecol Oncol 1990;39(2):115-8.
14. Deppe G, Malviya VK, Boike G, Malone JM Jr. Use of Cavitron surgical aspirator for debulking of diaphragmatic metastases in patients with advanced carcinoma of the ovaries. Surg Gynecol Obstet 1989;168(5):455-6.
15. Nicklin JL, Copeland LJ, O'Toole RV, Lewandowski GS, Vaccarello L, Havenar LP. Splenectomy as part of cytoreductive surgery for ovarian carcinoma. Gynecol Oncol 1995;58(2):244-7.
16. Rose PG. The cavitational ultrasonic surgical aspirator for cytoreduction in advanced ovarian cancer. Am J Obstet Gynecol 1992;166(3):843-6.
17. Benedetti-Panici P, Maneschi F, Scambia G, Cutillo G, Greggi S, Mancuso S. The pelvic retroperitoneal approach in the treatment of advanced ovarian carcinoma. Obstet Gynecol 1996;87(4):532-8.
18. Potter ME, Partridge EE, Hatch KD, Soong SJ, Austin JM, Shingleton HM. Primary surgical therapy of ovarian cancer: how much and when. Gynecol Oncol 1991;40(3):195-200.
19. Eisenkop SM, Spirtos NM. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival? Gynecol Oncol 2001;82:435-41.
20. Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS, et al. Paclitaxel for platinum refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Referral center 9103. J Clin Oncol 1993;11: 2405-10.
21. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92(9):699-708.
22. Muggia FM, Braly PS, Brady MF, Sutton G, Niemann PH, Lentz SL, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2000;18(1):106-15.
23. du Bois A, Richter B, Warm M, et al. for the AGO Study Group. Cisplatin/paclitaxel vs carboplatin/paclitaxel as 1st-line treatment in ovarian cancer. Proc ASCO 1998;17:A1395, 361a.
24. Kaye SB, Vasey PA. Docetaxel in ovarian cancer: phase III perspectives and future development. Semin Oncol 2002;(3 Suppl 12):22-7.
25. Look KY, Muss HM, Blessing JA, Morris M. A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Am J Clin Oncol 1995;18:19-22.
26. Lorusso V, Catino A, Leone B, Rabinovich M, Gargano G, Paradiso A, et al. Carboplatin plus ifosfamide as salvage treatment of epithelial ovarian cancer: a pilot study. J Clin Oncol 1995;11:1952-6.
27. Stiff PJ, Bayer R, Kerger C, Potkul RK, Malhotra D, Peace DJ, et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 1997;5:1309-17.
28. ten Bokkel Huinink WW, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183-93.
29. Vergote I, Himmelmann A, Frankendal B, Scheistroen M, Vlachos K, Trope C. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. Gynecol Oncol 1992;47:282-6.
30. Sutton GP, Blessing JA, Homesley HD, et al. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1989;7(11):1672-6.
31. Markman M, Hakes T, Reichman B, Lewis JL Jr, Rubin S, Jones W, et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1992;10(2):243-8.
32. Hatch KD, Beecham JB, Blessing JA, Creasman WT. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen: a Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 1991;68(2):269-71.
33. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998;16(2):405-10.
34. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997;15(3):987-93.
35. Friedlander M, Millward MJ, Bell D, Bugat R, Harnett P, Moreno JA, et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 1998;9(12):1343-5.
36. Lund B, Neijt JP. Gemcitabine in cisplatin-resistant ovarian cancer. Semin Oncol 1996;23(5 Suppl 10):72-6.
37. Bookman MA, Malmstrom H, Bolis G, Gordon A, Lissoni A, Krebs JB, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998;16(10):3345-52.
38. Williams L. The role of secondary cytoreductive surgery in epithelial ovarian malignancies. Oncology 1992;6:25-32.
39. Morris M, Gershenson DM, Wharton JT. Secondary cytoreductive surgery in epithelial ovarian cancer: nonresponders to first line therapy. Gynecol Oncol 1989;33: 1-5.
40. Michel G, Zarcas D, Castaigne D, Prade M. Secondary cytoreductive surgery in ovarian cancer. Eur J Surg Oncol 1989;15:201-4.
41. Vergote IB, De Wever I, Decloedt J, Tjalma W, Van Gramberen M, van Dam P. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Semin Oncol 2000;27(3 Suppl 7):31-6.
42. Vergote IB. Phase III randomized study of neoadjuvant chemotherapy followed by interval debulking surgery versus upfront cytoreductive surgery followed by chemotherapy with or without interval debulking surgery in patients with stage IIIc or IV ovarian epithelial, peritoneal, or fallopian tube cancer. Protocol EORTC-55971. http://cancernet.nci.nih.gov.
43. van der Burg MEL, van Lent M, Buyse M, Koblerska A, Columbo N, Favlli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced ovarian cancer. N Engl J Med 1995;332:629-34.
44. Ozols RF, Bundy BN, Fowler J, et al. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 158). Proc ASCO 1999;18:A-1373, 356a.
45. Nicoletto MO, Tumolo S, Talamini R, Salvagno L, Franceschi S, Visona E, et al. Surgical second look in ovarian cancer: a randomized study in patients with laparoscopic complete remission - a Northeastern Oncology Cooperative Group-Ovarian Cancer Cooperative Group study. J Clin Oncol 1997;15(3):994-9.
46. Podratz KC, Schray MF, Wieand HS, Edmonson JH, Jefferies JA, Long HJ, et al. Evaluation of treatment and survival after positive second-look laparotomy. Gynecol Oncol 1988;31(1):9-24.
47. Heintz AP, Van Oosterom AT, Trimbos JB, Schaberg A, Van der Velde E, Nooy M. The treatment of advanced ovarian carcinoma (II): interval reassessment operations during chemotherapy. Gynecol Oncol 1988;30(3):359-71.
48. Hoskins WJ, Rubin SC, Dulaney E, Chapman D, Almadrones L, Saigo P, et al. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma. Gynecol Oncol 1989;34(3): 365-71.
49. Potter ME, Hatch KD, Soong SJ, Partridge EE, Austin JM Jr, Shingleton HM. Second-look laparotomy and salvage therapy: a research modality only? Gynecol Oncol 1992;44(1):3-9.
50. Hempling RE, Wesolowski JA, Piver MS. Second-look laparotomy in advanced ovarian cancer: a critical assessment of morbidity and impact on survival, Ann Surg Oncol 1997;4(4):349-54.
51. Williams L, Brunetto VL, Yordan E, DiSaia PJ, Creasman WT. Secondary cytoreductive surgery at second-look laparotomy in advanced ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 1997;66(2):171-8.
52. Gadducci A, Iacconi P, Fanucchi A, Cosio S, Teti G, Genazzani AR. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer. Anticancer Res 2000;20(3B):1959-64.
53. Obermaier A, Sevelda P. Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients. Acta Obstet Gynecol Scand 2001;80(5):432-6.
54. Munkarah A, Levenback C, Wolf JK, Bodurka-Bevers D, Tortolero-Luna G, Morris RT, et al. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol 2001;81(2):237-41.
55. Phase III Randomized Study of Chemotherapy With or Without Secondary Cytoreductive Surgery in Patients With Recurrent Ovarian Epithelial. EORTC-55963. http://clinicaltrials.gov. Accessed December, 2002.
56. Salom E, Almeida Z, Mirhashemi R. Management of recurrent ovarian cancer: evidence-based decisions. Curr Opin Oncol 2002;14(5):519-27.
57. Alberts DS, Liu PY, Hannigan EV, et al. Phase III study of intraperitoneal (IP) cisplatin (CDDP)/intravenous (IV) cyclophosphamide (CPA) in patients with optimal disease stage III ovarian cancer: a AWOG-GOG-ECOG Intergroup study. Proc ASCO 1995;14:273 [abstract].
58. Los G, McVie JG. Experimental and clinical status of intraperitoneal chemotherapy. Eur J Cancer 1990;26:755-62.
59. Stephens AD, Alderman R, Chang D, Edwards GD, Esquivel J, Sebbag G, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 1999;6(8):790-6.
60. Jacquet P, Stephens AD, Averbach AM, Chang D, Ettinghausen SE, Dalton RR, et al. Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 1996;77(12):2622-9.
61. Vaart PJM, Vange N, Zoetmulder FAN, Goethem AR, Tellingen O, ten Bokkel Huinink WW, et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 1998;34:148-54.
62. Deraco M, Rossi CR, Pennacchioli E, Guadagni S, Somers DC, Santoro N, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori 2001;87(3):120-6.
63. Steller MA, Egorin MJ, Trimble EL, Bartlett DL, Zuhowski EG, Alexander HR, et al. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother Pharmacol 1999;43:106-14.
64. Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995;221(1):29-42.
65. Sugarbaker PH. Complete parietal and visceral peritonectomy of the pelvis for advanced primary and recurrent ovarian cancer. Cancer Treat Res 1996;81:75-87.
66. Ceelen WP, Hesse U, de Hemptinne B, Pattyn P. Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer. Br J Surg 2001;88(1):152.
67. Vaupel PW. The influence of tumor blood flow and microenvironmental factors on the efficacy of radiation, drugs and localized hyperthermia. Klin Padiatr 1997;209(4):243-9.
68. Los G, van Vugt MJ, Pinedo HM. Response of peritoneal solid tumors after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer 1994;69:235-41.
69. Engelhardt R. Hyperthermia and drugs. Recent Results Cancer Res 1987;104:136-203.
70. Teicher BA, Kowal CD, Kennedy KA, Sartorelli AC. Enhancement by hyperthermia of the in vitro cytotoxicity of mitomycin C toward hypoxic tumor cells. Cancer Res 1981;41:1096-9.
71. Hettinga JVE, Lemstra W, Meijer C, Dam WA, Uges DRA, Konings AWT, et al. Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumor cells. Br J Cancer 1997;75:1735-43.
72. Deraco M, Vaglini M, Santinami M, Costagli V, Di Re F, Inglese MG, et al. Razionale per un trattamento chemioipertermico della carcinosi peritoneale. Argomenti Oncol 1995;16:149-59.
73. van der Vange N, van Goethem AR, Zoetmulder FA, Kaag MM, van de Vaart PJ, ten Bokkel Huinink WW, et al. Extensive cytoreductive surgery combined with intraoperative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. Eur J Surg Oncol 2000;26(7):663-8.
74. Steller MA, Egorin MJ, Trimble EL, Bartlett DL, Zuhowski EG, Alexander HR, et al. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother Pharmacol 1999;43:106-14.
75. Nicoletto MO, Padrini R, Galeotti F, Ferrazzi E, Cartei G, Riddi F, et al. Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer. Cancer Chemother Pharmacol 2000;45:457-62.
76. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. BMJ 1991;303:884-93.
77. Bartellet DL, Buell JF, Libutti SK, et al. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer 1998;83(6):1251-61.
78. Los G, Sminia P, Wondergem J, Mutsaers PH, Havemen J, ten Bokkel Huinink D, et al. Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer 1991;27:472-7.
79. Masuda H, Tanaka T, Matsushima S. Hyperthermic enhancement of cisplatin-induced generation of active oxygen radicals in a cell-free system. Anticancer Res 1998;18:1473-7.
80. Hettinga JV, Konings AW, Kampinga HH. Reduction of cellular cisplatin resistance by hyperthermia - a review. Int J Hyperthermia 1997;13:439-57.
81. Cohen CJ. Surgical considerations in ovarian cancer. Semi Oncol 1985;12:53-6.
82. Los G, McVie JG. Carboplatin: an alternative for intraperitoneal cisplatin treatment in cancers restricted to the peritoneal cavity? Proc Am Soc Clin Oncol 1990;abstract 608.
83. ten Bokkel Huinink WW, Heintz APM, Dubbelman R, Franklin H, Mcvie JG. Intraperitoneal carboplatin for refractory ovarian cancer: phase I study. Proceedings of the Second International Conference of intracavitary Chemotherapy. San Diego; 1988. p. 47.
84. Speyer J, Beller U, Colombo N, et al. A phase I trial of intraperitoneal carboplatin (CBDCA) in women with ovarian cancer. Proceedings of the second International Conference of Intracavitary Chemotherapy. San Diego; 1988. p. 120.
85. Pfeiffer P, Bennendbaek O, Bertelsen K. Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancer. Gynecol Oncol 1990;36:306-11.
86. Jacquet P, Averbach A, Stuart OA, Chang D, Sugarbaker PH. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother Pharmacol 1998;41(2):147-54.
87. Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Young RC. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 1979;39(8):3209-14.
88. Ozols RF, Young RC, Speyer JL, Sugarbaker PH, Greene R, Jenkins J, et al. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancers. Cancer Res 1982;42:4265-9.
89. Haveman J, Rietbroek RC, Geerdink A, Van Rijn J, Bakker PJ. Effect of hyperthermia on the cytotoxicity of 2′,2′-difluorodeoxycytidine (gemcitabine) in cultured SW1573 cells. Int J Cancer 1995;62(5):627-30.
90. Pestieau SR, Belliveau JF, Griffin H, Stuart OA, Sugarbaker PH. Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies. J Surg Oncol 2001;76(2):106-14.
91. Markman M, Brady MF, Spirtos NM, Hanjani P, Rubin SC. Phase II trial of intraperitoneal Paclitaxel in carcinoma of the ovary, tube and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol 1998;16:2620-4.
92. Rossi CR, Foletto M, Mocellin S, Pilati PL, De Simone M, Deraco M, et al. Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis. Cancer 2002;94:492-9.
93. Vaglini M, Deraco M, Santinami M, Re F, Inglese MG, Manzi R, et al. Chemioipertermia intraperitoneale; tecnica chirurgica. Argomenti Oncol 1995;16:161-7.
94. Sugarbaker PH, Jacquet P, Stephens AD, Stuart OA, Averbach AM. Comparison of covered versus closed technique for heated intraoperative chemotherapy for peritoneal carcinomatosis from gastrointestinal cancer. In: Abe O, Inokuchi K, Takasaki K, editors. XXX World congress of the International College of surgeons. Bologna, Italy: Monduzzi Editore; 1996. p. 389-93.
95. Leunig M, Goetz AE, Dellian M, Zetterer G, Gamarra F, Jain RK, et al. Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response. Cancer Res 1992;52(2):487-90.
96. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988;48(24 Pt 1):7022-32.
97. Hager ED, Dziambor H, Hohmann D, Muhe N, Strama H. Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer. Int J Gynecol Cancer 2001;11(Suppl 1):57-63.
98. Raspagliesi F, Deraco M, Rossi CR. Stage III/IV epithelial ovarian cancer with macroscopic residual disease after 1st line chemotherapy: a multicentric prospective randomised study comparing loco regional approach + systemic chemotherapy vs. systemic chemotherapy alone. http://www.sitilo.org.
99. Howell SB, Pfeifle CE, Wung WE, Olshen RA. Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res 1983;43:1426-31.
100. ten Bokkel Huinink WW, Dubbelma R, Aartsen A, Franklin H, Mcvie JG. Experimental and clinical results of intraperitoneal cisplatin. Semin Oncol 1985;12:43-6.
101. Pretorius RG, Hacker NF, Berek JS, Ford LC, Hoeschele JD, Butler TA, et al. Pharmacokinetics of ip cisplatin in refractory ovarian carcinoma. Cancer Treat Rep 1983;67:1085-92.
102. Othman T, Goto S, Lee JB, Taimura A, Matsumoto T, Kosaka M. Hyperthermic enhancement of the apoptotic and antiproliferative activities of paclitaxel. Pharmacology 2001 May;62(4):208-12.